SCHEMBL4591277

SCHEMBL4591277

Cc1nc2c3c(ccn2c1C)[C@](C)(O)[C@H](O)[C@@H](c1ccccc1)O3

nearest known ligand 0.36

Predicted protein targets (top 7)

geneUniProtsupporting neighboursconfidence
ATP4A P20648 3/20 0.36
ATP4B P51164 3/20 0.36
CYP3A4 P08684 2/20 0.31
CYP2C9 P11712 2/20 0.31
CYP1A2 P05177 1/20 0.30
CYP2D6 P10635 1/20 0.30
CYP2C19 P33261 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4591325 1.00 ATP4A (0.36) ATP4AATP4BCYP3A4CYP2C9CYP1A2
SCHEMBL5989299 1.00 ATP4A (0.36) ATP4AATP4BCYP3A4CYP2C9CYP1A2
SCHEMBL4731626 0.90 ATP4A (0.35) ATP4AATP4B
SCHEMBL4735663 0.90 ATP4A (0.35) ATP4AATP4B
SCHEMBL4877115 0.86 ATP4A (0.35) ATP4AATP4B
SCHEMBL4985180 0.86 ATP4A (0.36) ATP4AATP4BCYP3A4CYP2C9CYP1A2
SCHEMBL4737170 0.85 ATP4A (0.35) ATP4AATP4BCYP3A4CYP2C9CYP1A2
SCHEMBL4732829 0.85 ATP4A (0.35) ATP4AATP4BCYP3A4CYP2C9CYP1A2
SCHEMBL4884349 0.84 ATP4A (0.36) ATP4AATP4B
SCHEMBL5744691 0.84 ATP4A (0.36) ATP4AATP4B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1879891-A1 MUTUAL PRODRUG COMPOUNDS FOR USE AS ANTIINFLAMMATORY AGENTS WITH GASTROINTESTINAL PROTECTIVE ACTIVITY Nycomed GmbH (DE) 2008-01-23 EP claimed
EP-1877410-A1 MUTUAL PRODRUG COMPOUNDS FOR USE AS ANTIINFLAMMATORY AGENTS WITH GASTROINTESTINAL PROTECTIVE ACTIVITY Nycomed GmbH (DE) 2008-01-16 EP claimed
WO-2006117315-A1 MUTUAL PRODRUG COMPOUNDS FOR USE AS ANTIINFLAMMATORY AGENTS WITH GASTROINTESTINAL PROTECCTIVE ACTIVITY NYCOMED GMBH (DE) 2006-11-09 WO claimed
WO-2006117316-A1 MUTUAL PRODRUG COMPOUNDS FOR USE US ANTIINFLAMMATORY AGENTS WITH GASTROINTESTINAL PROTECTIVE ACTIVITY NYCOMED GMBH (DE) 2006-11-09 WO claimed
US-20060241134-A1 Pharmaceutical combinations of a proton pump inhibitor and a compound which modifies gastrointestinal motility ALTANA PHARMA GA (DE) 2006-10-26 US claimed
US-20060154954-A1 Combinations and use of selected pharmaceutically active compounds ALTANA PHARMA AG (DE) 2006-07-13 US claimed
EP-1599175-A2 IMIDAZOPYRIDINES CONTAINING COMBINATIONS AND THEIR USE IN TREATING GASTROINTESTINAL INFLAMMATORY DISORDERS ALTANA Pharma AG (DE) 2005-11-30 EP claimed
US-20050020637-A1 Agents for the treatment of airway disorders ALTANA PHARMA AG (DE) 2005-01-27 US claimed
EP-1453493-A2 REVERSIBLE PROTON PUMP INHIBITORS FOR THE TREATMENT OF AIRWAY DISORDERS ALTANA Pharma AG (DE) 2004-09-08 EP claimed
WO-2004071391-A2 IMIDAZOPYRIDINES CONTAINING COMBINATIONS AND THEIR USE IN TREATING GASTROINTESTINAL INFLAMMATORY DISORDERS ALTANA PHARMA AG (DE) 2004-08-26 WO claimed
WO-2003043614-A2 REVERSIBLE PROTON PUMP INHIBITORS FOR THE TREATMENT OF AIRWAY DISORDERS ALTANA PHARMA AG (DE) 2003-05-30 WO claimed
WO-2008058990-A1 7,7-DISUBSTITUTED PYRANO-[2,3-C]-IMIDAZO-[1,2-A]-PYRIDINE DERIVATIVES AND THEIR USE AS GASTRIC ACID SECRETION INHIBITORS NYCOMED GMBH (DE) 2008-05-22 WO disclosed
US-20080102133-A1 Oral Pharmaceutical Preparation for Proton Pump Antagonists ALTANA PHARMA AG (DE) 2008-05-01 US disclosed
US-20080050428-A1 Oral Pharmaceutical Preparation Comprising a Proton Pump Antagonist and a Basic Excipient ALTANA PHARMA AG (DE) 2008-02-28 US disclosed
EP-1879891-A1 MUTUAL PRODRUG COMPOUNDS FOR USE AS ANTIINFLAMMATORY AGENTS WITH GASTROINTESTINAL PROTECTIVE ACTIVITY Nycomed GmbH (DE) 2008-01-23 EP disclosed
US-6916825-B2 Alkylated imidazopyridine derivatives ALTANA PHARMA AG (DE) 2005-07-12 US disclosed
US-20050020637-A1 Agents for the treatment of airway disorders ALTANA PHARMA AG (DE) 2005-01-27 US disclosed
WO-2004105795-A1 PHARMACEUTICAL COMBINATIONS OF A PROTON PUMP INHIBITOR AND A COMPOUND WHICH MODIFIES GASTROINTESTINAL MOTILITY ALTANA PHARMA AG (DE) 2004-12-09 WO disclosed
WO-2004071391-A2 IMIDAZOPYRIDINES CONTAINING COMBINATIONS AND THEIR USE IN TREATING GASTROINTESTINAL INFLAMMATORY DISORDERS ALTANA PHARMA AG (DE) 2004-08-26 WO disclosed
US-20030158193-A1 Alkylated imidazopyridine derivatives ALTANA PHARMA AG (DE) 2003-08-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030158193-A1 Alkylated imidazopyridine derivatives CYP2E1, SLC10A2, FABP2 ATP4A 276/4885ATP4B 1054/4885CYP3A4 14/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.